PMID- 21967065
OWN - NLM
STAT- MEDLINE
DCOM- 20120320
LR  - 20231120
IS  - 1936-086X (Electronic)
IS  - 1936-0851 (Linking)
VI  - 5
IP  - 11
DP  - 2011 Nov 22
TI  - Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy.
PG  - 8591-9
LID - 10.1021/nn202070n [doi]
AB  - Tumor targetability and site-specific drug release of therapeutic nanoparticles 
      are key factors for effective cancer therapy. In this study, poly(ethylene 
      glycol) (PEG)-conjugated hyaluronic acid nanoparticles (P-HA-NPs) were 
      investigated as carriers for anticancer drugs including doxorubicin and 
      camptothecin (CPT). P-HA-NPs were internalized into cancer cells (SCC7 and 
      MDA-MB-231) via receptor-mediated endocytosis, but were rarely taken up by normal 
      fibroblasts (NIH-3T3). During in vitro drug release tests, P-HA-NPs rapidly 
      released drugs when incubated with cancer cells, extracts of tumor tissues, or 
      the enzyme Hyal-1, which is abundant in the intracellular compartments of cancer 
      cells. CPT-loaded P-HA-NPs (CPT-P-HA-NPs) showed dose-dependent cytotoxicity to 
      cancer cells (MDA-MB-231, SCC7, and HCT 116) and significantly lower cytotoxicity 
      against normal fibroblasts (NIH-3T3) than free CPT. Unexpectedly, high 
      concentrations of CPT-P-HA-NPs demonstrated greater cytotoxicity to cancer cells 
      than free CPT. An in vivo biodistribution study indicated that P-HA-NPs 
      selectively accumulated into tumor sites after systemic administration into 
      tumor-bearing mice, primarily due to prolonged circulation in the blood and 
      binding to a receptor (CD44) that was overexpressed on the cancer cells. In 
      addition, when CPT-P-HA-NPs were systemically administrated into tumor-bearing 
      mice, we saw no significant increases in tumor size for at least 35 days, 
      implying high antitumor activity. Overall, P-HA-NPs showed promising potential as 
      a drug carrier for cancer therapy.
CI  - (c) 2011 American Chemical Society
FAU - Choi, Ki Young
AU  - Choi KY
AD  - Department of Life and Nanopharmaceutical Sciences, Kyung Hee University, Seoul 
      130-701, Republic of Korea.
FAU - Yoon, Hong Yeol
AU  - Yoon HY
FAU - Kim, Jong-Ho
AU  - Kim JH
FAU - Bae, Sang Mun
AU  - Bae SM
FAU - Park, Rang-Woon
AU  - Park RW
FAU - Kang, Young Mo
AU  - Kang YM
FAU - Kim, In-San
AU  - Kim IS
FAU - Kwon, Ick Chan
AU  - Kwon IC
FAU - Choi, Kuiwon
AU  - Choi K
FAU - Jeong, Seo Young
AU  - Jeong SY
FAU - Kim, Kwangmeyung
AU  - Kim K
FAU - Park, Jae Hyung
AU  - Park JH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111011
PL  - United States
TA  - ACS Nano
JT  - ACS nano
JID - 101313589
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drug Carriers)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 80168379AG (Doxorubicin)
RN  - 9004-61-9 (Hyaluronic Acid)
RN  - XT3Z54Z28A (Camptothecin)
SB  - IM
MH  - Animals
MH  - *Antineoplastic Agents/metabolism/pharmacology
MH  - Biological Transport
MH  - Camptothecin/metabolism/pharmacology
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Doxorubicin/metabolism/pharmacology
MH  - Drug Carriers/*chemistry/metabolism/pharmacokinetics
MH  - Humans
MH  - Hyaluronic Acid/*chemistry
MH  - Mice
MH  - NIH 3T3 Cells
MH  - Nanoparticles/*chemistry
MH  - Polyethylene Glycols/*chemistry
MH  - Xenograft Model Antitumor Assays
EDAT- 2011/10/05 06:00
MHDA- 2012/03/21 06:00
CRDT- 2011/10/05 06:00
PHST- 2011/10/05 06:00 [entrez]
PHST- 2011/10/05 06:00 [pubmed]
PHST- 2012/03/21 06:00 [medline]
AID - 10.1021/nn202070n [doi]
PST - ppublish
SO  - ACS Nano. 2011 Nov 22;5(11):8591-9. doi: 10.1021/nn202070n. Epub 2011 Oct 11.